A comparison of human G-Csf and human Gm-Csf given concurrently with anti-cancer chemotherapy

Background: Anti-cancer chemotherapy is associated with a myriad nail changes ranging from cosmetic disfigurement to severe changes which may require an alteration in the cancer chemotherapeutic regimens. The objective of the study was to analyse the nail changes in patients undergoing cancer chemotherapy.Methods: Screening was done for all in-patients undergoing cancer chemotherapy and out-patients referred to Dermatology from Oncology. All nail changes were documented according to a proforma and an attempt was made to establish a relation, if any, with a chemotherapeutic agent group.Results: A total of consecutive 150 patients undergoing cancer chemotherapy were screened, out of which nail changes were observed in 50 patients. The age group of patients ranged from 12yrs to 73yrs. The Male: Female ratio was 2.7:1. Following platinum based agents, the nail changes were seen in 54% of patients. There was a significant association of nail changes following chemotherapy with a p value of 0.00001%. Pigmentary changes were the most common nail plate changes. Longitudinal pigmentary bands were the most common pigmentary nail plate changes seen in 67.7% of patients following chemotherapy with platinum based agents, and 16.1% of patients following CHOP regimen. Diffuse pigmentation of nail plate was most common nail plate change (16.1%) following chemotherapy with taxanes. Muehrcke’s lines were the most common nail bed changes seen in 57.1% of patients following treatment with platins. Half and half nails and onycholysis were seen in 42.85% of patients following CHOP chemotherapy. Pigmentation of the nail folds were the most common changes seen in 40% of patients following platinum based agents and CHOP chemotherapy.Conclusions: A variety of nail changes can be associated with cancer chemotherapy. A knowledge about the various changes ranging from those of cosmetic concern to serious changes in patients who are undergoing chemotherapy is vital for the successful management of the patient.

Download Full-text

Survey on Adverse Events with Use of Antiemetics during Anti-cancer Chemotherapy

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ◽

10.5649/jjphcs.37.225 ◽

2011 ◽

Vol 37 (4) ◽

pp. 225-231

Author(s):

Masaki Yoshino ◽

Mayumi Kaise ◽

Yoshimi Tanaka ◽

Haruki Nagai

Keyword(s):

Adverse Events ◽

Cancer Chemotherapy ◽

Anti Cancer

Download Full-text

PEG-rhG-CSF Use Reduces Glucose Level Significantly in Cancer Patients Receiving Chemotherapy

Proceedings of Anticancer Research ◽

10.26689/par.v4i6.1680 ◽

2020 ◽

Vol 4 (6) ◽

Author(s):

Shasha Cui ◽

Xinqiang Liu ◽

Dayan Zhang ◽

Lu Zhang ◽

Ying Wang

Keyword(s):

Cancer Patients ◽

Cancer Chemotherapy ◽

Side Effect ◽

Fasting Blood Glucose ◽

Time Interval ◽

Glucose Levels ◽

Significant Difference ◽

Anti Cancer ◽

Chemotherapy Induced Neutropenia ◽

Mean Glucose

Background: In patients receiving anti-cancer chemotherapy, polyethylene glycolated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) was used for prophylaxis of chemotherapy-induced neutropenia. However, the side effect of PEG-rhG-CSF use on fasting blood glucose (FBG) level remains unclear. Materials and Methods: Cancer patients receiving chemotherapy and PEG-rhG-CSF were enrolled in our study. Baseline glucose (Glucose 1) was measured before PEG-rhG-CSF use, a second FBG test (Glucose 2) was performed after PEG-rhG-CSF use. Mean glucose levels were compared using t test. Results: The time interval between PEG-rhG-CSF use and the second glucose test was 2.4±1.5 days. The mean Glucose 1 was 5.18±0.53 mmol/L, and Glucose 2 was 3.80±1.13 mmol/L. Statistical analysis showed a significant difference between Glucose 1 and 2 existed (P<0.001). Conclusion: Our study identifies a hypoglycemic side effect of PEG-rhG-CSF occurs in cancer patients undergoing anti-cancer chemotherapy. Our results highlight the caution required when using PEG-rhG-CSF for prophylaxis of chemotherapy-induced neutropenia.

Download Full-text

Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release

Current Medicinal Chemistry ◽

10.2174/0929867325666180111095913 ◽

2018 ◽

Vol 25 (16) ◽

pp. 1837-1866 ◽

Cited By ~ 29

Author(s):

Qi Tang ◽

Bing Yu ◽

Lilong Gao ◽

Hailin Cong ◽

Na Song ◽

...

Keyword(s):

Side Effects ◽

Drug Release ◽

Cancer Chemotherapy ◽

Material Science ◽

Cancer Drug ◽

Stimuli Responsive ◽

The Past ◽

Anti Cancer ◽

Stimuli Response ◽

Therapeutic Responses

Conventional drugs used for cancer chemotherapy have severe toxic side effects and show individually varied therapeutic responses. The convergence of nanotechnology, biology, material science and pharmacy offers a perspective strategy for cancer chemotherapy. Nanoparticles loaded with anti-cancer drug have been designed to overcome the limitations associated with conventional drugs, several nanomedicines have been approved by FDA and shown good performances in clinical practice. However, the therapeutic efficacies cannot be enhanced. Taking this into account, stimuli responsive nanoparticles present the ability to enhance therapeutic efficacy and reduce side effects. In this review, we systematically summarized the recent progresses of controlled anti-cancer drug release systems based on nanoparticles with different stimuli response including pH, temperature, light, redox and others. If the achievements of the past can be extrapolated into the future, it is highly likely that responsive nanoparticles with a wide array of desirable properties can be eventually developed for safe and efficient cancer therapy.

Download Full-text